While the number and types of indoor air pollutants is rising, much is suspected but little is known about the impact of their potentially synergistic interactions, upon human health. Highly susceptible populations include children, allergy and asthma sufferers, and a low socioeconomic background, however no specific guidance is available. SynAir-G aims to reveal and quantify synergistic interactions between different pollutants affecting health, from mechanisms to real-life, focusing on the school setting. We will develop a comprehensive and responsive multipollutant monitoring system, advance environmentally friendly interventions, and disseminate the generated knowledge to relevant stakeholders in accessible and actionable formats. To achieve these objectives, SynAir-G will construct and deploy novel and improved sensors of chemical and biological (allergens, microbes) pollutants. These will be tested in a real-world setting, in participating schools of 5 countries around Europe and eventually combined into a multisensing platform. In the same setting, pollutants will be linked to their sources and two eco-friendly air-purifying devices will be assessed. Health outcome data will be obtained from children using a gamified app and prospective monitoring, respecting privacy. Highly susceptible children, such as those with allergy or asthma, will act as sentinels to increase sensitivity of the system, that will be able to provide stratified (susceptibility-specific) alerts. Explainable AI will support the near-real time analysis and response. In parallel, cell and mouse models will evaluate the mechanisms and complex dose-responses of the synergistic parameters. SynAir-G will thus provide FAIR data on air pollutants and their sources, a comprehensive and personalized user-friendly solution to monitoring indoor air quality, and proposals for possible interventions and an improved regulatory framework, robustly supporting the Zero Pollution Action Plan. SynAir-G is part of the Indoor air and health cluster.

3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions, SMEs, and 8 major pharmaceutical companies, teamed to study a fundamental issue in medicine: the mechanisms of response and non-response to therapies, the major aim of 3TR, both within single disease entities and across diseases, where molecular stratification may identify shared disease taxonomies. The molecular identification of groups of patients to whom a drug will benefit, will allow focusing on those who are drug orphan. Harmonization of data from existing academy or industry-sponsored studies will identify biomarkers to inform a new collection. Specimens of diseased tissues, blood, stools, and other fluids will be obtained in a de novo observational prospective trial with standard of care medication prior, during and after first or second line of treatment. Because the studies will be at different phases of progression, a carrousel model of work was designed for input and output of data to be continuously analysed, and interpreted, to inform those measurements to be undertaken and allow cross-validation of results. The 3TR team will elucidate the role of the microbiome, genetics and regulatory genomic features in disease progression. The working aims of 3TR are: 1) establish a centralized data management platform; 2) perform comprehensive molecular and clinical characterisation of a prospective patient cohort; 3) establish integrated analysis of all data using advanced bioinformatics/statistical and modelling methods; 4) identify sets of predictive biomarkers of response/non-response to therapies; 5) improve the competitiveness of European industry and support development of novel solutions. 3TR will sustain beyond the project end the samples and its knowledge base. 3TR will challenge and revolutionize the conventional single-disease based approach with important implications in future disease treatment.

Chronic obstructive pulmonary disease (COPD) is a highly prevalent chronic condition. While COPD is a lung disease, it is mainly the exacerbations and extrapulmonary comorbidities which affect the quality of life, health care costs, and prognosis. The optimal COPD treatment needs to focus on both the characteristics and consequences of the lung disease itself and the diagnosis and treatment of comorbidities. While the severity of lung function impairment is routinely assessed, the exacerbations, the associated comorbidities and limitations in daily life are still significantly underestimated. A personalized approach to COPD management is needed to specifically address the disease, prevent exacerbations, and mitigate its comorbidities to obtain a positive impact on patient health and quality of life. TOLIFE will clinically validate an artificial intelligence (AI) solution to process daily life patient data captured by unobtrusive sensors to enable optimised personalised treatment, assessment of health outcomes and improved quality of life in COPD patients. The TOLIFE approach to COPD management, targeted to predict and mitigate exacerbations and continuously assess the health outcomes, has the potential to reduce mortality, improve health related quality of life and reduce the healthcare costs. TOLIFE will develop and clinically validate an AI-based platform for the early prediction of exacerbations and assessment of the health outcomes. Prediction of exacerbations and assessment of health outcomes will be exploited by clinicians through a patient management tool to perform early and personalized treatment. TOLIFE platform will inform through a disease information tool the patient and caregivers about the patient's health status, the specific treatment plan and lifestyle indications. Two clinical studies will be implemented, one to collect data for AI-tools development and the other to validate the effectiveness of TOLIFE to reduce the risk of exacerbations.

Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enormous heterogeneity with regard to disease outcome and response to targeted therapies, which currently cannot be adequately anticipated to tailor individual patient management. Hence, mechanistic understanding of this heterogeneity and biomarkers predictive for disease control and therapy response over time are important prerequisites of a future precision medicine in IMIDs. ImmUniverse has been formed as a European transdisciplinary consortium to tackle these unmet needs and to understand the role of the crosstalk between tissue microenvironment and immune cells in disease progression and response to therapy of two different IMIDs: ulcerative colitis and atopic dermatitis. Following this unique cross-disease approach ImmUniverse will fill the gap and the limitations of current studies, which do not systematically compare the complex interactions between recirculating immune cells and the respective tissue microenvironment. The consortium will combine analysis of tissue-derived signatures with “circulating signatures” detectable in liquid biopsies, employing state-of-the-art profiling technologies corresponding to multi-Omics datasets. The project will also bring diagnostics in IMID to a new level by implementing disruptive non-invasive liquid-biopsy methodology in combination with novel, validated circulating biomarker assays which are expected to improve diagnosis, inform early in the clinical course on disease severity and progression and enable treatment response monitoring. The identified signature will be validated to monitor state/progression and response to therapy in prospective observational cohorts. Realization of these objectives will result in improvement of patient management, lead to increased patient well-being and will significantly reduce the socioeconomic burden of these diseases.